EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 270 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Cancer Control in American Indian and Alaska Native Populations: A Conversation... April 25, 2018 Navigating Your Care During Long-Term Cancer Survivorship June 25, 2020 “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Dog Showers His Mom with Snuggles and Makes Her Laugh During... December 6, 2021 Load more HOT NEWS Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... Women Diagnosed with Early Breast Cancer Since 2000 Have About a... Life beyond cancer: Improving the long term side effects for children... ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to...
